相关实验视频
Updated: Jan 15, 2026

10:22
Humanized Mediator Release Assay as a Read-Out for Allergen Potency
Published on: June 29, 2021
3.9K
具有优化的破坏性功效的高亲和力奥马利祖马布变体可以在体内防止过敏反应
Daniel Brigger1, Pascal Guntern1, Luke F Pennington2
1Department of BioMedical Research, University of Bern, Bern, Switzerland; Department of Rheumatology and Immunology, University Hospital Bern, Bern, Switzerland.
The Journal of allergy and clinical immunology
|October 13, 2025
概括
新的抗IgE抗体显示出10倍更高的亲和力和更强的功效,有效地中和IgE,并预防小鼠模型中的过敏反应. 这些下一代疗法为过敏症状提供了增强的治疗选择.
科学领域:
- 免疫学 免疫学 免疫学
- 过敏研究 研究过敏
- 生物技术是生物技术.
背景情况:
- 奥马利祖马布是一种向IgE的单克隆抗体,用于过敏症,但由于中等亲和力,需要频繁高剂量.
- 现有的下一代抗IgE抗体已经显示出安全性或有效性限制.
- 需要改进抗IgE疗法,提高结合亲和力和效力.
研究的目的:
- 设计具有增加IgE结合亲和力和表位特异性的奥马利祖马布变体.
- 开发具有增强功能的抗体,以积极分离IgE与FcεRI.
- 提高抗IgE治疗的疗效和治疗潜力.
主要方法:
- 在突变的Omalizumab库中使用了酵母显示选择.
- 确定了抗IgE克隆C03和工程灵活变体C03-H1L2和C03-H2L2.
- 评估了IgE结合亲和力,FcεRI结合抑制和IgE排位功效.
主要成果:
- C03抗体的IgE结合亲和力比奥马利祖马布高10倍.
- 工程变体显示出IgE与FcεRI结合的优异抑制.
- C03变种有效地取代了FcεRI结合的IgE,而没有诱导细胞激活,并在单剂量后预防小鼠的过敏反应.
结论:
- 对于下一代抗IgE疗法来说,更高的亲和力和破坏性强度至关重要.
- 改造的C03变种代表了抗IgE治疗的有希望的进步.
- 这些发现支持优化当前针对过敏疾病的治疗策略.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
Cross-reactivity
32.8K
Overview
32.8K
Antibody Actions
2.3K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
2.3K
Antiasthma Drugs: Muscarinic Receptor Antagonists
1.7K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.7K
Affinity and Avidity
38.5K
Overview
38.5K

